Literature DB >> 17565238

Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis.

Takefumi Matsuo1, Hiroko Kobayashi, Miyako Matsuo, Keiko Wanaka, Hidetomo Nakamoto, Hiroyuki Matsushima, Rumi Sakai.   

Abstract

The aim of this study was to determine the frequency of heparin/platelet factor (PF) 4 complex antibodies in 305 uremic patients treated with chronic intermittent hemodialysis using unfractionated heparin or low-molecular-weight heparin for 3 months. Heparin-induced thrombocytopenia (HIT) antibodies were detected by ELISA in 7 patients (2.3%) who had no history of HIT. Two patients abruptly developed HIT associated with the formation of clots in the extracorporeal circuit after they were found to be carrying HIT antibodies. These patients were suspected to have a similar trigger: an increased dose of recombinant human erythropoietin (rHuEPO). The drug might induce parallel changes in hematocrit (Ht) levels and platelet counts until the onset of HIT. After the onset of HIT, a parallel phenomenon between Ht and platelet counts was not found because of the thrombocytopenia due to HIT. Although HIT onset has been reported during the initial phase of dialysis sessions, there have been few reports on the onset of HIT in uremic patients on dialysis with long-term heparin anticoagulation. In this study, HIT was observed in 2 uremic patients on chronic dialysis with intermittent use of heparin. In some patients on chronic intermittent dialysis carrying HIT antibodies, HIT may occur following rHuEPO treatment. The presence of HIT should be borne in mind in chronic dialysis patients carrying HIT antibodies for 3 months or more.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17565238     DOI: 10.1159/000102052

Source DB:  PubMed          Journal:  Pathophysiol Haemost Thromb        ISSN: 1424-8832


  10 in total

1.  Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis.

Authors:  Yvette C Tanhehco; Ann H Rux; Bruce S Sachais
Journal:  Transfusion       Date:  2010-10-26       Impact factor: 3.157

2.  Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients.

Authors:  Chieh Kuo; Chiang-Chin Tsai; Chien-An Chen; Yueh-Feng Tsai; Yen-Hsun Chen
Journal:  Acta Cardiol Sin       Date:  2017-03       Impact factor: 2.672

3.  Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients.

Authors:  Yueh-Feng Tsai; Chien-An Chen; Chieh Kuo; Kao-Chang Lin
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

4.  Anti-platelet factor 4/heparin antibody is associated with progression of peripheral arterial disease in hemodialysis patients.

Authors:  Yen-Hsun Chen; Kao-Chang Lin; Yueh-Feng Tsai; Lai-King Yu; Li-Hsueh Huang; Chien-An Chen
Journal:  Int Urol Nephrol       Date:  2015-07-22       Impact factor: 2.370

5.  Vaccine-induced immune thrombotic thrombocytopenia presenting as a mimic of heparin-induced thrombocytopenia in a hemodialysis patient receiving ChAdOx1 nCoV-19 vaccine.

Authors:  Yi-Ling Lin; Chen-Yuan Lin; Jiung-Hsiun Liu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 6.  Heparin-induced thrombocytopenia: a renal perspective.

Authors:  Samaha Syed; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

Review 7.  Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors:  Jenny I Shen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

8.  Investigation of a potential protective mechanism against heparin-induced thrombocytopenia in patients on chronic intermittent hemodialysis.

Authors:  Yvette C Tanhehco; Adam Cuker; Michael Rudnick; Bruce S Sachais
Journal:  Thromb Res       Date:  2013-01-08       Impact factor: 3.944

9.  The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up.

Authors:  Delong Zhao; Xuefeng Sun; Li Yao; Hongli Lin; Jijun Li; Jiuyang Zhao; Zhimin Zhang; Lide Lun; Jianrong Zhang; Mingxu Li; Qi Huang; Yang Yang; Shimin Jiang; Yong Wang; Hanyu Zhu; Xiangmei Chen
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

10.  Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin.

Authors:  Satish Maharaj; Simone Chang; Karan Seegobin; James Morales; Agnes Aysola; Fauzia Rana; Marwan Shaikh
Journal:  Exp Hematol Oncol       Date:  2018-09-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.